Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 2
1979 1
1981 1
1982 2
1984 2
1985 2
1986 2
1987 2
1989 1
1991 1
1993 2
1996 3
1997 2
1998 6
1999 3
2000 3
2001 11
2002 6
2003 7
2004 4
2005 7
2006 11
2007 10
2008 18
2009 11
2010 12
2011 11
2012 15
2013 17
2014 10
2015 11
2016 17
2017 15
2018 21
2019 18
2020 18
2021 27
2022 32
2023 23
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

323 results

Results by year

Filters applied: . Clear all
Page 1
Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report.
Andrade RJ, Aithal GP, de Boer YS, Liberal R, Gerbes A, Regev A, Terziroli Beretta-Piccoli B, Schramm C, Kleiner DE, De Martin E, Kullak-Ublick GA, Stirnimann G, Devarbhavi H, Vierling JM, Manns MP, Sebode M, Londoño MC, Avigan M, Robles-Diaz M, García-Cortes M, Atallah E, Heneghan M, Chalasani N, Trivedi PJ, Hayashi PH, Taubert R, Fontana RJ, Weber S, Oo YH, Zen Y, Licata A, Lucena MI, Mieli-Vergani G, Vergani D, Björnsson ES; IAIHG and EASL DHILI Consortium. Andrade RJ, et al. Among authors: heneghan m. J Hepatol. 2023 Sep;79(3):853-866. doi: 10.1016/j.jhep.2023.04.033. Epub 2023 May 8. J Hepatol. 2023. PMID: 37164270 Free PMC article. Review.
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
Kowdley KV, Bowlus CL, Levy C, Akarca US, Alvares-da-Silva MR, Andreone P, Arrese M, Corpechot C, Francque SM, Heneghan MA, Invernizzi P, Jones D, Kruger FC, Lawitz E, Mayo MJ, Shiffman ML, Swain MG, Valera JM, Vargas V, Vierling JM, Villamil A, Addy C, Dietrich J, Germain JM, Mazain S, Rafailovic D, Taddé B, Miller B, Shu J, Zein CO, Schattenberg JM; ELATIVE Study Investigators’ Group; ELATIVE Study Investigators' Group. Kowdley KV, et al. Among authors: heneghan ma. N Engl J Med. 2024 Feb 29;390(9):795-805. doi: 10.1056/NEJMoa2306185. Epub 2023 Nov 13. N Engl J Med. 2024. PMID: 37962077 Clinical Trial.
Reply.
Chung Y, Heneghan MA. Chung Y, et al. Among authors: heneghan ma. Hepatology. 2022 Sep;76(3):E67-E68. doi: 10.1002/hep.32579. Epub 2022 Jun 11. Hepatology. 2022. PMID: 35587539 No abstract available.
A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
Schattenberg JM, Pares A, Kowdley KV, Heneghan MA, Caldwell S, Pratt D, Bonder A, Hirschfield GM, Levy C, Vierling J, Jones D, Tailleux A, Staels B, Megnien S, Hanf R, Magrez D, Birman P, Luketic V. Schattenberg JM, et al. Among authors: heneghan ma. J Hepatol. 2021 Jun;74(6):1344-1354. doi: 10.1016/j.jhep.2021.01.013. Epub 2021 Jan 21. J Hepatol. 2021. PMID: 33484775 Free article. Clinical Trial.
Reply.
Rahim MN, Heneghan MA. Rahim MN, et al. Among authors: heneghan ma. Liver Transpl. 2019 Oct;25(10):1590-1591. doi: 10.1002/lt.25611. Epub 2019 Aug 20. Liver Transpl. 2019. PMID: 31344310 No abstract available.
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
Hirschfield GM, Shiffman ML, Gulamhusein A, Kowdley KV, Vierling JM, Levy C, Kremer AE, Zigmond E, Andreone P, Gordon SC, Bowlus CL, Lawitz EJ, Aspinall RJ, Pratt DS, Raikhelson K, Gonzalez-Huezo MS, Heneghan MA, Jeong SH, Ladrón de Guevara AL, Mayo MJ, Dalekos GN, Drenth JPH, Janczewska E, Leggett BA, Nevens F, Vargas V, Zuckerman E, Corpechot C, Fassio E, Hinrichsen H, Invernizzi P, Trivedi PJ, Forman L, Jones DEJ, Ryder SD, Swain MG, Steinberg A, Boudes PF, Choi YJ, McWherter CA; ENHANCE Study Group*. Hirschfield GM, et al. Among authors: heneghan ma. Hepatology. 2023 Aug 1;78(2):397-415. doi: 10.1097/HEP.0000000000000395. Epub 2023 Apr 6. Hepatology. 2023. PMID: 37386786 Free PMC article. Clinical Trial.
Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group.
Pape S, Snijders RJALM, Gevers TJG, Chazouilleres O, Dalekos GN, Hirschfield GM, Lenzi M, Trauner M, Manns MP, Vierling JM, Montano-Loza AJ, Lohse AW, Schramm C, Drenth JPH, Heneghan MA; International Autoimmune Hepatitis Group (IAIHG) collaborators(‡). Pape S, et al. Among authors: heneghan ma. J Hepatol. 2022 Apr;76(4):841-849. doi: 10.1016/j.jhep.2021.12.041. Epub 2022 Jan 20. J Hepatol. 2022. PMID: 35066089 Free article.
Reply.
Rahim MN, Heneghan MA. Rahim MN, et al. Among authors: heneghan ma. Liver Transpl. 2019 Sep;25(9):1457-1458. doi: 10.1002/lt.25606. Liver Transpl. 2019. PMID: 31323692 No abstract available.
Autoimmune hepatitis.
Heneghan MA, Yeoman AD, Verma S, Smith AD, Longhi MS. Heneghan MA, et al. Lancet. 2013 Oct 26;382(9902):1433-44. doi: 10.1016/S0140-6736(12)62163-1. Epub 2013 Jun 14. Lancet. 2013. PMID: 23768844 Review.
Reply.
Rahim MN, Heneghan MA. Rahim MN, et al. Among authors: heneghan ma. Liver Transpl. 2020 Jul;26(7):956-957. doi: 10.1002/lt.25751. Epub 2020 Apr 15. Liver Transpl. 2020. PMID: 32168403 No abstract available.
323 results